MXPA04006079A - Compuestos para el tratamiento de la disfuncion sexual. - Google Patents

Compuestos para el tratamiento de la disfuncion sexual.

Info

Publication number
MXPA04006079A
MXPA04006079A MXPA04006079A MXPA04006079A MXPA04006079A MX PA04006079 A MXPA04006079 A MX PA04006079A MX PA04006079 A MXPA04006079 A MX PA04006079A MX PA04006079 A MXPA04006079 A MX PA04006079A MX PA04006079 A MXPA04006079 A MX PA04006079A
Authority
MX
Mexico
Prior art keywords
treatment
sexual dysfunction
dopamine
receptor agonists
selective dopamine
Prior art date
Application number
MXPA04006079A
Other languages
English (en)
Inventor
Kwok-Fung Wong Stephen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA04006079A publication Critical patent/MXPA04006079A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

El uso de una composicion que comprende un agonista del receptor D3 dopamina selectivo, en donde dicho agonista del receptor D3 dopamina es al menos aproximadamente 15 veces mas funcionalmente selectivo para un receptor D3 dopamina como se compara con un receptor D2 dopamina cuando se mide usando la misma prueba funcional, en la preparacion de un medicamento para el tratamiento y/o prevencion de la disfuncion sexual.
MXPA04006079A 2001-12-18 2002-12-10 Compuestos para el tratamiento de la disfuncion sexual. MXPA04006079A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130219.9A GB0130219D0 (en) 2001-12-18 2001-12-18 Compounds for the treatment of sexual dysfunction
PCT/GB2002/005595 WO2003051370A1 (en) 2001-12-18 2002-12-10 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
MXPA04006079A true MXPA04006079A (es) 2004-09-27

Family

ID=9927832

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006079A MXPA04006079A (es) 2001-12-18 2002-12-10 Compuestos para el tratamiento de la disfuncion sexual.

Country Status (15)

Country Link
US (1) US20060052435A1 (es)
EP (1) EP1463508A1 (es)
JP (2) JP4214057B2 (es)
KR (1) KR20040068299A (es)
CN (1) CN1617727A (es)
AU (1) AU2002352372A1 (es)
BR (1) BR0215064A (es)
CA (1) CA2470624A1 (es)
GB (1) GB0130219D0 (es)
IL (1) IL162455A0 (es)
MX (1) MXPA04006079A (es)
NZ (1) NZ533513A (es)
PL (1) PL370842A1 (es)
WO (1) WO2003051370A1 (es)
ZA (1) ZA200403906B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149416A0 (en) 1999-11-19 2002-11-10 Solvay Pharm Bv Human enzymes of the metalloprotease family
AU2003267769A1 (en) * 2002-10-25 2004-05-13 Pharmacia & Upjohn Company Llc Use of heterocyclic amine-type compounds as neuroprotective agents
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
PL377480A1 (pl) * 2002-12-10 2006-02-06 Pfizer Inc. Pochodne morfoliny do stosowania jako agoniści dopaminy w leczeniu między innymi dysfunkcji seksualnej
WO2005116027A2 (en) * 2004-05-26 2005-12-08 Pfizer Limted Indazole and indolone derivatives and their use as pharmaceuticals
EP1758862A1 (en) * 2004-05-27 2007-03-07 Pfizer Limited Aminopyridine derivatives as selective dopamine d3 agonists
EP2354136B1 (en) 2008-10-10 2016-02-24 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Novel dopamine d3 receptor ligands and preparation and medical uses of the same
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
US20100318371A1 (en) * 2009-06-11 2010-12-16 Halliburton Energy Services, Inc. Comprehensive hazard evaluation system and method for chemicals and products
CN114113628A (zh) * 2021-11-08 2022-03-01 华东师范大学 多巴胺d2受体在嗅觉外周调控及制备治疗嗅觉异常药物中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US2599000A (en) * 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
JPS5742862B2 (es) * 1974-05-18 1982-09-10
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
US4929641B1 (en) * 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
US5750646A (en) * 1987-09-24 1998-05-12 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
US5877277A (en) * 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5767236A (en) * 1990-05-09 1998-06-16 Biomeasure, Inc. Linear therapeutic peptides
US5620959A (en) * 1990-07-31 1997-04-15 Glaxo Wellcome Inc. Bombesin antagonists
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9213215D0 (en) * 1992-06-20 1992-08-05 Wellcome Found Peptides
US5462926A (en) * 1992-07-27 1995-10-31 Biomeasure, Inc. Neuromedin B receptor antagonists which demonstrate selectivity
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
AU4844396A (en) * 1995-03-01 1996-09-18 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
US5650395A (en) * 1995-03-13 1997-07-22 Hurel; Steven Treatment of pulmonary hypertension
US5849863A (en) * 1995-09-08 1998-12-15 University Of Colorado Cytolytic bradykinin antagonists
FR2767825A1 (fr) * 1997-09-01 1999-02-26 Adir Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CU23063A3 (es) * 1997-11-12 2005-07-19 Bayer Ag Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas
AR022230A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
GEP20063783B (en) * 2001-03-28 2006-04-10 Pfizer N-Phenpropylcyclopentyl-Substituted Glutaramide Derivatives as Inhibitors of Neutral Endopeptidase Enzyme (NEP) for Treating Female Sexual Dysfunction (FSAD)

Also Published As

Publication number Publication date
ZA200403906B (en) 2005-06-22
US20060052435A1 (en) 2006-03-09
WO2003051370A8 (en) 2003-10-02
CA2470624A1 (en) 2003-06-26
BR0215064A (pt) 2004-10-13
GB0130219D0 (en) 2002-02-06
IL162455A0 (en) 2005-11-20
JP2008266338A (ja) 2008-11-06
NZ533513A (en) 2006-04-28
WO2003051370A1 (en) 2003-06-26
CN1617727A (zh) 2005-05-18
EP1463508A1 (en) 2004-10-06
AU2002352372A1 (en) 2003-06-30
JP4214057B2 (ja) 2009-01-28
KR20040068299A (ko) 2004-07-30
JP2005516014A (ja) 2005-06-02
PL370842A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
PT954314E (pt) Formas de dosagem farmaceutica para melhorar a disfuncao erectil masculina
GEP20043203B (en) EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
WO2004047838A3 (de) Pharmazeutische zusammensetzung aus beta-3-adrenozeptor-agonisten und antimuskarinika
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
AR020442A1 (es) Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
WO2004091593A3 (en) Methods for the treatment of pain comprising opioid antagonists
CA2432203A1 (en) Sustained release drug delivery devices with multiple agents
MXPA03004141A (es) Agonistas del receptor alfa activado del proliferador de peroxisomas.
ZA200409333B (en) 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2B and alpha-2C adrenergic receptors.
AP2003002755A0 (en) Guanidinobenzamides as mc4-r agonists
NZ577392A (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
MXPA04006079A (es) Compuestos para el tratamiento de la disfuncion sexual.
PL346876A1 (en) Mglur5 antagonists for the treatment of pain and anxiety
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
WO2006068713A3 (en) 3,3'-diindolylmethane immune activating compositions
WO2002041894A3 (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
AP2005003325A0 (en) Morpholine derivatives for use as dopamine agonists in the treatment of I.A. sexual dysfunction
WO2004000219A3 (en) Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof
SI1450782T1 (sl) Uporaba kombinirane zmesi, ki vsebuje propionil L-karnitin in dodatna zdravila za zdravljenje erektivne disfunkcije
TW200621304A (en) Pharmaceutical composition
EP1260221A3 (en) Combination treatment for depression and anxiety
EA200200839A1 (ru) Композиции с контролируемым высвобождением, содержащие агонист и антагонист опиоидов
WO2006130022A8 (en) Modulation of ovulation by agonists and antagonists of bmprii
BR0015310A (pt) Uso de agonistas do receptor de dopamina d3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal